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Summary Small cell bronchial carcinoma (SCC) xenografts with differing sensitivity to cyclophosphamide
(CY) were investigated using a variety of techniques. Two xenografts (HX78 and HX88) were relatively
sensitive to CY, one xenograft (HX72) was inherently resistant to CY and a fourth xenograft (HX78Cy) was
a CY induced resistant subline of HX78 and was unstable when maintained without CY exposure.
Conventional light microscopy, cytology and electron microscopy examination of the xenografts revealed
appearances consistent with SCC. An antikeratin antibody demonstrated the presence of keratin in the
inherant and the induced resistant xenografts (and in the unstable revertant) but not in the two sensitive
xenografts; the presence of keratin suggested squamous differentiation. Monolayer culture morphology of the
sensitive HX78 and the unstable revertant was anchorage independent with the cells forming floating
aggregates; the induced resistant subline of this xenograft (HX78Cy) showed, by contrast, flattened, angular
adherent cells. PHCG production was detected in the monolayer culture supernatant of sensitive HX78 cells;
the level of production of /HCG was increased in the induced resistant HX78Cy cells. Karyotype and flow
cytometry studies were also performed. The morphological responses of small cell lung cancer to treatment
are discussed.
In a previous publication (Berman & Steel, 1984),
in vivo investigations on induced and inherent
resistance in human small cell lung cancer (SCC)
xenografts were described. Specimens from three
patients were established in immune suppressed
mice and the sensitivity of the xenografts to a
variety of alkylating agents was determined using
growth delay as the end-point. Clinical chemo-
sensitivity data were available in two cases for
comparison. In the first, the patient was found to
have disease of low sensitivity and this was reflected
in the response of the corresponding xenograft. The
second patient, in contrast, was found to have
relatively chemosensitive disease and again this was
reflected in the xenograft response.
In one of the xenografts repeated treatment with
cyclophosphamide (CY) led to induced resistance.
The resistant line was about 8-fold less sensitive
than the parent line but even after a year of
repeated treatment, complete abolition of response
was not achieved. When the CY resistant line was
tested with a variety of other agents, a broad
pattern of cross resistance was observed. It was also
found that the CY resistant phenotype was
unstable.
The investigations described here were designed
to evaluate the biological basis of the observed
drug resistance.
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Materials and methods
Xenografts
Tissue from three patients with small-cell lung
cancer was used, as described previously (Berman &
Steel. 1984). The donor of HX72 (diagnosed from
bronchoscopy specimens) had shown a partial
response (PR) to cyclophosphamide (CY), CCNU
and methotrexate (MTX) but then showed evidence
of disease progression some 3 months after chemo-
therapy had been started. A tumour specimen was
taken from a s.c. nodule after chemotherapy and
established as a xenograft. The donor of HX88
showed a complete response to ifosphamide but
later relapsed after 19 months. Further chemo-
therapy with mAMSA (4'-(9-Acridinylamino)
methanesulfon-m-anisidide) and etoposide was tried
without success. The xenograft specimen was taken
from a supraclavicular fossa mass before any
chemotherapy had been given. The histology of the
clinical specimen revealed extensive infiltration by
carcinoma. However, classification was difficult
because of lack of differentiation and considerable
crush artefact. The established xenograft
appearances were those of small cell lung cancer.
The post-mortem histology was of mixed small cell
and large cell anaplastic carcinoma of the bronchus.
The donor of HX78 had disseminated small cell
carcinoma at diagnosis. Bronchoscopic material was
established as a xenograft. The disease progressed
rapidly and chemotherapy was not given to the
patient.
Details of xenograft establishment have been
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reported previously (Shorthouse et al., 1980). The
methods of drug treatment, in vivo tumour
measurement, and assessment of response using the
growth delay end-point, have been described
(Berman & Steel, 1984).
Histology and immunohistochemistry
Haematoxylin and eosin-stained slides were
prepared from sections of xenograft material and
the results reviewed by one of us (B.G.). Some
sections were kindly reviewed by Dr J. Sloane
(Royal Marsden Hospital). Tumours were classified
according to the WHO Scheme (Kreyberg et al.,
1967). The Periodic Acid Schiff (PAS) stain was
used to detect the presence of mucins and the
Grimelius' argyrophil reaction was used to detect
neurosecretory granules. Antisera against keratin
extracts of human callous were used to identify
keratin in the lung tumour xenografts, according to
the method described by Mitchell & Gusterson,
1982. This antibody has been shown to identify
areas of squamous metaplasia in the bronchial
mucosa and to stain foci of squamous differen-
tiation in lung tumours (Gusterson et al., 1982).
The specificity of staining was confirmed by
absorption of the antiserum with mgml-I of a
purified callous keratin extract at room temperature
for 1.5h. Incubation of sections with the absorbed
antiserum completely abolished the staining. For
electron microscopy, small fresh tumour fragments
were fixed with 2% glutaraldehyde and then post-
fixed with 1% osmium tetroxide; thin sections were
stained with uranyl acetate and lead citrate and
examined with a Philips E.M.400 electron
microscope by Dr P. Monaghan (Ludwig Institute,
London). For cytological studies, 8 x 103 dye-
excluding cells in 0.2ml, prepared by enzymatic
disaggregation, were introduced into the cytocentri-
fuge chambers of a Shandon Elliot cytocentrifuge,
set to run at 1500r/min for 5min. The slides were
fixed in 100% methanol for 2min then stained with
1 in 20 buffered Giemsa for 15min. The slides were
washed under running water and dried in a warm
air cabinet before mounting. Cytological
appearances were kindly reviewed by P.A. Trott
(Royal Marsden Hospital).
Cell suspensions
Two methods of disaggregation were employed:
mechanical and enzymatic.
Mechanical method Tumour dissected from a
freshly killed mouse, was weighed and rinsed in a
Falcon tube with PBS. The tumour was chopped in
a petri dish using crossed scalpels. Pieces aspirated
by a Pasteur pipette were transferred to a Falcon
tube and further rinsed with PBS. After 10min
incubation at 37°C in a water-bath, the tube was
given 2-3 sharp shakes. The larger pieces were
allowed to settle and the cell suspension aspirated
off into a tube containing 0.5ml foetal bovine
serum (FBS). The cell suspension was centrifuged
for 4min at 1000r/min and then resuspended in
8ml Ham's F12 medium, containing 15% FBS
before filtration through a 20pm filter. The filtrate,
at 1: 10 dilution, was kept in vertical tubes for 1 h
at 4°C before the top half of the cell suspension
was aspirated off for further use. Cell counts were
performed with a haemocytometer.
Enzymatic method An enzyme cocktail was
prepared with 20mg collagenase, 50mg pronase
and 20mg DNase, made up in 10ml Ham's F12
medium without serum. A 0.45 m millipore filter
was used for sterilization. This solution was used at
1:10 dilution; storage at 4°C. Tumour pieces,
prepared as in the mechanical method, were added
to the dilute cocktail ( -250mg tissue to each
10ml) and then left for 30min in horizontally
positioned tubes at room temperature. The mixture
was then given 2-3 sharp shakes and 2ml of serum
added to terminate the enzyme action. Thereafter,
the cell suspension was handled as in the
mechanical method.
Cell size determination
Cell suspensions, prepared enzymatically, were
diluted with Isoton and cell size distribution
measured by means of a Coulter Counter.
Monolayer/suspension culture
One ml cell suspensions, prepared mechanically, at
dilutions of 104-106 cells ml-1 were introduced into
50ml tissue culture flasks with 2ml of culture
medium. Alternatively dilute tumour pieces were
employed. Flasks were gassed with 3% oxygen.
After 3 days, 5ml of culture medium was added
and a week later a further 5ml of culture medium
was added, the flasks being gassed on each
occasion.
/HCGproduction
flHCG released into the medium of
monolayer/suspension cultures was assayed by
means of the radioimmune assay method of
Shorthouse et al (1982) on material harvested at 2
weeks. This assay was kindly performed by Dr M.
Ellison and colleagues (Ludwig Institute, London).
Chromosome analysis
Tumour cell suspensions, prepared mechanically,
were incubated with colcemid 0.2jIgml-1 in saline
at 370C for 45min. They were then spun atRESISTANCE IN DIFFERENTIATION IN LUNG CANCER XENOGRAFTS 655
Table I Summary of response and biological findings on small
xenografts.
cell carcinoma of lung
HX78 HX78Cy HX88 HX72
Responsea to:
CY (100mgkg 1) 5.1 0.6 5.4 1.5
MeCCNU (10mgkg-1) 3.1 0 2.2 0.5
L-PAM (2.5mgkg ) 8.6 0.6 1.9 1.1
VCR (1.2mgkg ) 10.6 5.2 ND ND
XRAYS (2.OGy) 2.4 <0.5 ND ND
Growth rate:
Median doubling time (days) 7 7 6.5 6.0
Cell size:
Peak diameter (i) 11.12 10.45 9.04 9.66
Cytology and histology SCC SCC SCC SCC
Antikeratin Ab -ve +veb -ve +ve
PAS -ve -ve ND -ve
Grimelius -ve -veb ND +ve
EM SCC SCC ND SCC
Monolayer culture Floating Surfacec ND ND
morphology: aggregates adherence
HCG production Yes Increased None None
Karyotype: Mode 80; 41 71 64 47
Range (80-82); (70-76) (64-65) (47-48)
(39-41)
DNA content/cell
(relative to HX72) 1.96 1.77 ND 1.0
% G1 71.6 74.4 ND 81.4
%S 18.5 13.4 ND 10.0
%G2 9.9 12.2 ND 8.6
% host cells 6.5 9.4 ND d
aSpecific growth delay (i.e. volume doubling times saved).
b+ve in the revertant.
cFlating aggregates in the revertant.
dInseparable from G1 tumour cells.
ND-Not determined.
2000r/min for 3 min and then resuspended in 0.075
MKC1 for 10min. After twice respinning and
resuspending in 3 parts methanol: 1 part glacial
acetic acid, the slides were prepared by the air
drying method and stained with 5% Giemsa for
one minute.
Flow cytometry
Enzymatically prepared cell suspensions, at a
concentration of 106 cells ml-1, were stained with a
solution of 5mg ethidium bromide and 100mg
trisodium citrate per 100ml of water. An ortho-
cytofluorograph flow cytometer was used, exciting
at 480nm by Argon laser. Mouse bone marrow
provided the diploid standard. Cell cycle analysis
was performed by estimating the area under the
FCM profile, measured by weighing curve outline
cut-outs. Flow cytometry was carried out with the
assistance of T.C. Stephens, J. Peacock, M.
Ormerod and A. Payne (Institute of Cancer
Research and Ludwig Institute).
Results
Our earlier data on the response to chemotherapy
of the 4 xenograft lines are summarised at the top
of Table I (Berman & Steel, 1984). HX78 and
HX88 (lines that have never been exposed to
cytotoxic drug treatment) were responsive to CY.
By comparison, HX72 (tissue taken from a patient
who had shown a poor partial response to
combination chemotherapy, including the agent
CY) and HX78Cy (the induced resistant line from
HX78) showed much reduced sensitivity, by a
factor of -4.0 in the case of HX72 and 8.0 in the
case of HX78Cy. Cross resistance studies in
HX78Cy showed that its responsiveness to
MeCCNU, vincristine (VCR), melphalan (L-PAM)
and X-rays was also reduced.656 R. BERMAN et al.
Histology and immunohistochemistry
The biopsy material from the donor of HX78 and
xenografts derived from it, both in early and late
passages, had the appearance of SCC. The clinical
specimen, from the donor of HX72, and the
xenografts established from it, both in early and
late passages, again were of a similar pattern. They
revealed cells which, though relatively large for
SCC, were in all other features in keeping with a
diagnosis of SCC. The xenograft HX88 was
established from a supraclavicular fossa mass where
lack of differentiation and crush artefact prevented
classification of the clinical specimen; however the
xenografts consistently showed the morphology of
SCC. Post-mortem specimens were taken from this
patient, who had had a complete response to
chemotherapy, but eventually relapsed and failed to
respond to further chemotherapy. These specimens
showed the appearance of a mixed small-cell and
large-cell carcinoma of the bronchus.
The CY resistant subline xenograft, HX78Cy was
found to have appearance indistinguishable from
the parent line; similar findings were obtained for
HX78 previously treated with MeCCNU, which
was not associated with the emergence of a resistant
subline. CY treatment did not alter the appearance
of the other two xenografts, HX88 and HX72,
when compared with their respective parent lines.
The inherently resistant HX72 and the induced
resistant HX78Cy stained strongly with the
antikeratin antibody. In some areas the cells were
slightly larger and arranged nests which were
clearly delineated with the antibody suggesting the
presence of squamous elements (Figure 1). These
areas were not identifiable on the Haematoxylin
and eosin-stained sections. The more sensitive
HX88 and HX78, by contrast, stained weakly
positive to essentially negative with this antibody.
The sensitive HX78, after a single treatment with
CY, was not associated with an alteration of CY
response (Berman & Steel, 1984). After a single CY
treatment the staining of HX78 was indistinguish-
able from the untreated control. When HX78Cy
was grown on for two passages without CY
treatment, sensitivity to CY was found to return
(Berman & Steel, 1984). This revertant, HX78Cy-2
showed the majority of its cells to be positive.
Positivity was also found in adenocarcinoma
xenografts (HX70 and HX65) and most strongly of
all in a squamous cell carcinoma xenograft (HX79).
Glandular elements Of the three SCC xenografts
examined, none showed evidence of mucin
production.
Neuroendocrine elements Three SCC xenografts
were investigated, but only one, the inherently
resistant HX72, was found to be positive. The
induced resistant HX78Cy and its parent line,
HX78, were both negative.
Electron microscopy
EM appearances of HX78, HX78Cy and HX72
(HX88 not examined) were consistent with SCC
and the characteristic dense core vesicles were
evident in all specimens. Comparing HX78Cy with
HX78, nucleoli were more prominent, cell process
contained less glycogen and in general glycogen was
less dense. Tonofilaments and desmosomes
(squamous features) were unremarkable in both
HX78Cy and HX72.
Cytology
Examination of centrifuge preparations of cell
suspensions revealed that HX88, HX78, HX78Cy
and HX72, all had appearances of typical SCC
though in some preparations or parts of them,
morphology was more in keeping with lymphoid
cells.
Cell size analysis (Table I) showed that the mean
cell diameter in HX78Cy was slightly reduced by
comparison with HX78. Both, however, were
somewhat larger than HX88 or HX72.
Monolayer/suspension culture morphology
The appearances of HX78 and HX78Cy were found
to be quite different in these cultures. HX78 cells
remained typical of SCC grown in this manner, i.e.
they were anchorage independent and formed
floating aggregates. Only the occasional cell could
be seen adherent to the dish. HX78Cy cells, by
contrast, showed large numbers of cells adherent to
the dish, with a flattened and angular appearance;
far fewer cells formed floating aggregates. The
revertant, HX78Cy-3 (3rd passage without
treatment), had morphological features which had
reverted to those of the parent line, i.e. there was
loss of adherence.
JIHCG production
,BHCG production was found in HX78 cells, at a
level of 1.6-2.4ngml-1 in the monolayer culture
supernatant. HX78Cy, at a stage when it was
approximately seven times more resistant to CY
than the parent line, was found to produce some
five times the amount of,HCG than HX78.
Chromosome analysis andflow cytometry
All the xenografts contained human chromosomes.
As shown in Table I, there was no relationship of
modal chromosome number to drug sensitivity. TheRESISTANCE AND DIFFERENTIATION IN LUNG CANCER XENOGRAFTS 657
(a) 4 results of flow cytometry analysis are presented in
Vil ~~Table I. There was no obvious second tumour cell
m9gi Ei > ; peak for HX72, HX78 or HX78Cy. No second
.. m~~~~~~~~~ode, as found for HX78/10 by karyotype analysis,
was detected in HX78/15 using flow cytometry.
This may have been obscured by the presence of
the host cell peak, but no second G2 peak was
noted. The ratio of relative DNA content to
relative chromosome number however, reflects
.broad general agreement between the two methods
of analysis.
The percentage of host cells found in HX78 and
HX78Cy cells are low by comparison with the
values reported by Warenius (1980) using immuno-
fluorescent techniques on one colon carcinoma and
two bronchial squamous carcinoma xenografts.
Though only 3 xenografts were examined, as with
(b)_Xj . karyotype, there appeared to be no obvious
(b) ! S-'=< (relationship between relative DNA content/cell and
xenograft sensitivity. Cell cycle analysis showed the
sensitive HX78 cells to have a larger S phase
fraction (18.5%) than the more resistant HX78Cy
(13.4%) and HX72 (10%). These differences are in
broad agreement with flow cytometry results on
clinical SCC specimens. Raber et al (1980) found-
the S phase size to be 17.5% and Vindelov et atl
(1982) obtained a figure of 21.6%. The data of
Vindelov et alt. (1982) showed no correlation
between S phase size and tumour response.
Discussion
The present results show that resistance to
alkylating agents in xenografts of small cell lung
(c)entially negative stainingwiththisantibody. tumucancer is associated with features of squamous
differentiation. Although the resistant xenograft AF ~~~~~~~~~~lines maintained their gross histological character- istics, the immunohistochemical studies showed
*~ ~ ~ ~ ~~~~. evidence of keratin formation that was absent in
the drug sensitive lines. An exception to this
association was found in the case of the revertant
line HX78Cy-2, which had been through two
passages in the absence of CY treatment and
wich, although it had regained CY sensitivity, had
not lost its keratin positivity.
The first international classification of lung
tumours was published in 1967 by Kreyberg et at.
and using light microscopy alone, divided these
tumours into four main groups: Adenocarcinoma,
Epidermoid carcinoma, Large cell carcinoma and
Figure 1 Immunohistochemistry. The inherently Small cell anaplastic carcinoma. McDowell et at.
resistant xenograft HX72/23 (a) and the induced (1978, 1981) using light microscopy supplemented
resistant xenograft HX78Cy/14 (b) show positive by histochemistry and electron microscopy have
staining with the antikeratin antibody. HX88/13 a challenged this classification. They observed
more sensitive xenograft (c) shows weakly positive to features thought characteristic of one type of
essentially negative staining with this antibody. tumour to be present in the cells of other tumour
(Magnif'ication =500 x) types where these features would not normally be658 R. BERMAN et al.
expected. Hence, seven lung tumours were
diagnosed by McDowell et al. (1981), using light
microscopy, as large cell carcinoma, squamous cell
carcinoma or adenocarcinoma. Ultrastructural
studies showed, however, all these tumours to
contain numerous dense core granules; serotonin
was identified in six and argyrophilic granules were
demonstrated in 5 of 6 tested. These three features
are usually associated with neurosecretory cells.
Gusterson et al. (1982) identified keratin
immunoreactive cells in all eight epidermoid
carcinomas examined, but also in 6 out of 12 large
cell carcinomas, 2 out of 6 adenocarcinomas and 2
out of 15 small cell carcinomas. Hence there may
be heterogeneity of phenotypic expression in lung
tumours not normally recognisable at the light
microscopy level. Moreover, "local microenviron-
mental pressures" may result in differentiation
towards different morphological cell types
(McDowell et al., 1978, Gusterson, 1984); and the
concept of a distinct and different histogenesis for
each of the light microscopy groups may be
overstated.
Treatment itself may play a part in phenotypic
lability. There have been a number of clinico-
pathological studies of chemotherapy treated
patients where pretreatment diagnostic material has
been compared with autopsy findings. The studies
of Brereton et al. (1978), Matthews (1979) and
Abeloff & Eggleston (1981) have examined in this
way a large number of patients initially diagnosed
as having small cell lung cancer. At post-mortem
the findings have been, in as many as 14-33% of
cases, foci of various non-small cell elements in
addition to the predominantly small cell
component. In a smaller proportion of cases, 5.5-
12.5%, there was no identifiable small cell cancer
evident; these cases showed squamous cell
carcinomas, adenocarcinomas and large cell
carcinomas. Possible explanations were offered (1)
Non-representative initial biopsy, (2) Selective
eradication of the small-cell component of a mixed
tumour with subsequent growth of the initially
inconspicuous non-small component, (3) Cure of
the small cell tumour with emergence of a second
primary, (4) Alteration of cell differentiation of the
small cell tumour.
The results reported here favour postulates (2)
and/or (4). Much further investigation is necessary
to elucidate the histological and drug sensitivity
mechanisms; the present evidence encourages more
detailed studies of histological processes in small
cell lung cancers.
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